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 Introduction 
 Primary pancreatic carcinoma constitutes the vast 
majority of pancreatic malignancies: between 85 and 90% 
of all pancreatic tumors are included in this category  [1] . 
Metastatic carcinoma of the pancreas from another pri-
mary site is uncommon and represents a small group 
comprising between 2 and 5% of all pancreatic cancers 
 [2] . Metastatic tumors to the pancreas are clinically rare 
and are exceedingly difficult to differentiate from a pri-
mary pancreatic neoplasm; the reported incidence of 
these metastatic lesions in autopsy studies is in the range 
of 1–11% of widespread metastatic disease  [3] . There are 
a variety of cancers which have been shown to metasta-
size into the pancreas as mass lesions, such as colon can-
cer, non-small cell lung cancer and melanoma  [4] . In par-
ticular, primary kidney tumors have an increased dispo-
sition for metastasis to rare sites such as the pancreas  [5] . 
The difficulty of distinguishing between clear cell pri-
mary pancreatic tumors and solitary pancreatic metasta-
ses may lead to clinical misdiagnosis. In some cases the 
metastatic deposit in the pancreas is the primary mani-
festation of an unknown primary tumor. Therefore, an 
accurately defined elaboration of the medical history is 
critical for the diagnostic workup for tumors in the pan-
creas. Pancreatic resections were for many years associ-
ated with high rates of morbidity and mortality, but re-
cent data have clearly shown that pancreatic surgery in 
high-volume clinical centers is increasingly safe. For ex-
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 Abstract 
 Background: Pancreatic metastases from renal cell carcino-
ma (RCC) are clinically rare but highly resectable. The aim of 
this article is to identify patients who profit from pancreatic 
resection of RCC despite the invasiveness of the surgery. 
 Methods: Between January 1996 and December 2007, data 
from 744 patients were collected in a prospective pancre-
atic surgery database, and patients with metastasis into the 
pancreas from RCC were identified.  Results: Resective sur-
gery was performed in 14 patients with metastasis to the 
pancreas from RCC. Most patients were clinically asymptom-
atic. The median interval between primary treatment of RCC 
and occurrence of pancreatic metastasis was 94 months 
(range 32–158). The morbidity rate was 42.8%. Patients with 
a metastasis size  ! 2.5 cm had a much better survival after 
resection (100 months) than those with a metastasis size 
 1 2.5 cm (44 months). Moreover, the number of metastases 
predicts the survival after resection.  Conclusions: In pa-
tients with pancreatic metastases from RCC who have only 
limited disease, complete resection of all lesions can be suc-
cessfully performed with a low rate of complications. Thus, 
patients with a history of RCC should be monitored for more 
than 10 years after nephrectomy to detect recurrence. 
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ample, recent studies have shown that mortality after 
pancreatectomy has decreased to  ! 5% when performed 
by experienced surgeons  [6] . Today the indications for 
these operations have been extended even for patients 
with metastatic disease to the pancreas  [7] . The potential 
benefit of metastasectomy in renal cancer is well docu-
mented in the literature. So far, approximately 250 cases 
of pancreatic resections for metastatic renal cell carcino-
ma (RCC) have been reported in the literature  [8, 9] . In 
all studies, pancreatic resection was recommended in the 
presence of isolated pancreatic localization and when 
technically feasible. Especially for patients with the his-
tory of kidney primary tumors, resection of metastasis 
can improve quality of life as well as prognosis  [10] .
 The purpose of this article is to identify subgroups of 
patients who profit from pancreatic resection of RCC me-
tastases despite the invasiveness of the surgery. The ben-
efits of this procedure can be shown with improved safe-
ty and a relatively good prognosis with low morbidity and 
mortality rates after pancreatic resection of RCC metas-
tases.
 Materials and Methods 
 Between January 1996 and December 2007, 14 patients (8 
women and 6 men) with a median age of 64 years (range 54–74) 
were checked on a prospective database of all pancreatic resec-
tions (n = 744). All patients were admitted and treated at our de-
partment and diagnosed with a renal cell metastasis into the pan-
creas. A thorough follow-up was performed for every patient in-
cluding clinical examination, complete laboratory workup, yearly 
abdominal ultrasonography (US) and computed tomography 
(CT) scan on pathological findings in any of the other examina-
tions.
 Standard pancreatic resections were pylorus-preserving pan-
creatoduodenectomy (PPPD) or Whipple pancreatoduodenecto-
my for tumors in the head or uncinate process. Distal pancreatec-
tomy was performed for tumors in the pancreatic body or tail. 
Two patients were treated by local tumor excision ( table 1 ).
 An accurate preoperative staging was performed to exclude 
the presence of extrapancreatic metastases. All patients under-
went a CT scan and abdominal US. MRCP or MR angiography 
was additionally used for metastases in the pancreatic head. Pri-
mary tumor location, location of metastases, size of metastases 
and the interval between primary treatment and metastases (dis-
ease-free interval) were evaluated. Moreover, presenting symp-
toms, surgical treatment, perioperative morbidity and long-term 
mortality were evaluated.
 Continuous data are presented as means. Survival distribu-
tions were analyzed by the methods of Kaplan and Meier. Patients 
dying from other than cancer-related causes were censored for the 
Kaplan-Meier estimation. Differences were evaluated by the log-
rank test. A p value  ! 0.05 was considered to indicate statistical 
significance. All statistical analyses were performed with SPSS 
Version 15.0 (SPSS, Chicago, Ill., USA).
 Results 
 Among the 14 observed patients, 8 were women and 6 
were men; mean age was 64 years (range 54–74) ( table 1 ). 
The median interval from nephrectomy was 94 months 
(range 32–158). Primary RCC originated from the right 
kidney in 7 patients and from the left kidney in 7 patients. 
Most patients (10/14) were clinically asymptomatic, and 
the diagnosis of pancreatic metastasis was incidental dur-
Table 1. Characteristics and operative procedure for metastatic RCC
Case Age/
gender
Symptoms Primary tumor
stage of RCC
Time since
primary, months
Localization of 
metastasis
Follow-up
months
Operative
procedure
Status
1 66/f Asymptomatic pT3a N0 M0 G2 158 Head 14 Excision Alive
2 58/f Back pain pT3a N0 M0 G3 36 Body 111 PPPD Alive
3 63/f Asymptomatic pT2 N0 M0 G2 96 Tail 54 DPS Alive
4 54/m Jaundice pT2 N0 M0 G2 32 Head 75 Whipple Dead
5 66/m Asymptomatic pT2 N0 M0 G3 52 Head 49 Whipple Dead
6 58/f Jaundice pT3b N0 M0 G2 76 Head 15 Whipple Dead
7 74/m Jaundice pT2 N0 M0 G1 60 Head 116 Excision Dead
8 68/m Asymptomatic pT2 N1 M0 G3 120 Tail 0 DP Dead
9 64/f Asymptomatic pT3b N0 M0 G2 156 Head 14 PPPD Dead
10 58/f Asymptomatic pT2 N0 M0 G2 132 Tail 81 DPS Alive
11 70/f Asymptomatic pT3a N0 M0 G3 157 Head 19 PPPD Alive
12 70/m Asymptomatic pT2 N0 M0 G2 108 Tail 72 DP Dead
13 61/f Asymptomatic pT3b N1 M0 G3 46 Head 102 PPPD Dead
14 71/m Asymptomatic pT2 N0 M0 G2 84 Tail 12 DP Alive
PPPD = Pylorus-preserving pancreatoduodenectomy; DPS = distal pancreatectomy with splenectomy; DP = distal pancreatectomy.
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ing follow-up, mainly detected by US and CT. Four pa-
tients had the following symptoms: jaundice in 3 patients 
and back pain in 1 patient. Pancreatic metastases were 
located in the pancreatic head in 8 patients and in the tail 
in 5 patients. One patient had pancreatic metastases in 
the body. Solitary metastases were identified in 10 pa-
tients, and 4 patients had two or more metastases in the 
head, body and tail.
 All patients underwent radical resection. Resection 
margins were histologically negative for tumor infiltra-
tion in all patients (R0). The following surgical proce-
dures were performed: 4 pylorus-preserving pancreato-
duodenectomies, 5 distal pancreatectomies, 3 Whipple 
procedures and 2 excisions. In 3 cases we combined a dis-
tal resection with a splenectomy. Of the 14 patients, 6 pa-
tients were still alive at the end of the observation period 
(June 2008), whereas 8 patients had died. We observed 
one postoperative mortality 17 days after surgery because 
of an extended myocardial infarction. The morbidity rate 
was 42.8% ( table 2 ).
 One patient needed reoperation for intraperitoneal 
bleeding that occurred the first day after the Whipple 
procedure. The bleeding source was found in the right 
liver lobe after removal of extensive adhesions due to pre-
vious operations. Another patient developed a bleeding 
episode at the pancreatojejunostomy that was treated 
successfully by endoscopic intervention. Other complica-
tions included one pancreatic fistula (grade B according 
to Bassi et al.  [11] ), one lymphatic fistula and one postop-
erative pancreatitis. One patient had a major myocardial 
infarction as mentioned above. In this group of patients, 
all undergoing pancreatic resection, 6 patients are alive 
and free of disease. Median survival after pancreatic re-
Table 2. Surgical procedure and early postoperative outcome
Procedure n Complications n
Pylorus-preserving
pancreatoduodenectomy
4 Postoperative bleeding
Lymph fistula
1
1
Whipple procedure 3 Postoperative bleeding 1
Distal pancreatectomy 2 Myocardial infarction 1
Mortality 1
Distal pancreatectomy with
splenectomy 3 None
Excision 2 Pancreatitis 1
Pancreatic fistula 1
 Fig. 1. CT scan of a patient with renal cell metastasis in the pan-
creatic tail. 
Table 3. Analysis of factors predicting survival
Time since 
primary
mean value
months
Survival after
resection
mean value
months
RCC location
Right 107.0 n.s. 90.2Left 80.6 67.8
Metastasis location
Head 92 n.s. 66.3Other 96 98.0
Metastasis size
<2.5 cm 92.1 n.s. 100.9>2.5 cm 96.0 44.0
Time since primary
<60 months 84.2
>60 months 77.8
Gender
Female 107 n.s. 81.6
Male 76 78.0
Number of metastases
Solitary 104.7 n.s. 111.3
Multiple 74.0 49.4
Symptoms
Asymptomatic 98.9 n.s. 89.7
Jaundice 81.0 55.0
Operative procedure
Whipple/PPPD 79.3 n.s. 64.3
Distal resection
enucleation
108.3 101.3
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section was 75 months (95% confidence interval, 40.1–
109.9) ( fig. 1 ). Moreover, we analyzed factors predicting 
survival after pancreatic resections ( table 3 ). Survival was 
not predicted by the location of the RCC, location of the 
metastasis, time since resection of the primary tumor, 
gender, symptoms, operative procedure, blood loss or age 
of the patients.
 Patients with a metastasis size  ! 2.5 cm had a much 
better survival after resection (100.9 months) than those 
with a metastasis size  1 2.5 cm (44.0 months) ( fig. 2 , 3 ). 
The difference between the two groups was statistically 
significant (p = 0.01). Furthermore, we could show that 
the number of metastases predicts the survival after re-
section. The difference between patients with solitary 
metastasis and patients with multiple metastasis (111 vs. 
49 months) was statistically significant (p = 0.04).
 Discussion 
 Isolated metastatic disease to the pancreas is uncom-
mon relative to metastases to sites such as the liver, lungs 
and brain. Only about 250 cases have been published in 
the scientific literature so far. This is the first study that 
shows the results of pancreatic resections in patients with 
a RCC and limited disease.
 Metastatic RCC with pancreatic localization seems to 
represent a special clinical situation: pancreatic metasta-
sis typically occurs a long period after the initial nephrec-
tomy, but nevertheless it seems related to a good prognosis 
 [12, 13] . The largest single-center series of pancreatic re-
section for renal cell metastasis included 22 patients, and 
surgical resection was performed in 17 of these 22 patients 
 [13] . In a review, Hirota et al.  [14] gathered 66 cases of RCC 
metastatic to the pancreas of which 49 were surgically re-
sected. The median time between nephrectomy and the 
diagnosis of pancreatic metastasis was 8 years, which is 
similar to our series of patients, with a median of 8 years. 
Similar results have been previously reported, with a me-
dian interval after nephrectomy ranging from 6 to 12 
years  [15, 16] , the longest interval being 32 years  [12] .
 Therefore, patients with a history of RCC should be 
monitored for more than 10 years after nephrectomy to 
detect recurrence. It has been shown that complete surgi-
cal resection even for multiple pancreatic metastases 
from RCC is the most effective treatment option, leading 
to 5-year survival rates of up to 75%. Moreover, in pa-
tients with good general condition and limited disease, 
complete resection of all lesions, if surgically possible, 
can successfully be performed with low morbidity and 
mortality. Recent studies additionally have shown that 
partial resection can be performed laparoscopically with 
almost comparable results  [17, 18] . However, the opera-
tion should be performed in high-volume centers. Birk-
meyer et al.  [19–23]  showed that the 3-year survival after 
pancreatoduodenectomy was higher at high-volume cen-
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 Fig. 2. Kaplan-Meier curve of 14 patients undergoing pancreatic 
resection for metastases from RCC. 
 Fig. 3. Kaplan-Meier curve of survival depending on metastasis 
size. 
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ters (37%) than at medium- (29%), low- (26%), and very 
low-volume hospitals (25%).
 Schwarz et al.  [24]  have studied the impact of splenec-
tomy on hospital stay and survival after resection of pan-
creatic adenocarcinoma. In this analysis, splenectomy 
has no significant measurable impact on postoperative 
recovery, but has a negative influence on long-term sur-
vival independent of disease-related factors. The authors 
concluded that splenectomy should be avoided in the op-
erative treatment of exocrine pancreatic cancer at any lo-
calization. Even though in our study we just had 3 pa-
tients that were treated by distal pancreatectomy with 
splenectomy (DPS), these 2 patients had a better long-
term survival. Other authors showed that splenectomy 
has been linked to decreased long-term survival, e.g. for 
gastric cancer  [25] .
 Moreover, Choueiri et al.  [26] showed in a retrospec-
tively reviewed metastatic RCC database that right-sided 
kidney tumors had a better long-term prognosis than left-
sided ones. We can also confirm that patients with right-
sided kidney tumors had a better prognosis than those 
with RCC on the left side. Although there is not a good 
explanation so far, it is an interesting finding and should 
be looked at in further prognostication studies in RCC.
 The tumors in the present analysis involved the pan-
creatic head in 8 patients, while the other 6 patients had 
lesions in the pancreatic body or tail. Although data are 
still limited, renal metastases appear to be rather more 
frequent in the pancreatic head than in the body or tail.
 Solitary and small metastases in the pancreas are more 
common than multifocal involvement and seem to be re-
lated to a better prognosis  [12] . Our data show a signifi-
cant difference in survival after resection between pa-
tients with a metastasis size  ! 2.5 cm and patients that 
have pancreatic lesions  1 2.5 cm. These results differ from 
other studies of pancreatic resections; Carter et al.  [27] 
showed for ampullary tumors that the size of tumor did 
not predict survival.
 Similar results have just been shown in a recent study 
concerning renal cell metastases in the lungs. Assouad et 
al.  [28] showed that the size of RCC lung metastases is an 
important prognostic factor. The report includes 65 pa-
tients presenting with lung metastasis of RCCs; when the 
size of the metastasis was  1 2 cm, patients had signifi-
cantly shorter survival rates than those with smaller me-
tastases.
 Unlike liver or lung, the pancreas is a rather unusual 
site for metastasis. Other uncommon locations of RCC 
metastases include the ipsi- or contralateral adrenal glands 
and the contralateral kidney. Various attempts have been 
made to explain this type of metastasis. Some authors ad-
vocate venous spread along the collateral veins of the hy-
pervascular tumor with renal venous thrombosis  [29–31] . 
However, renal lymphatic drainage might be the predom-
inant way of metastasis, as retroperitoneal lymph node 
involvement may lead to a retrograde lymphatic backflow 
in the thoracic duct and the common para-aortic lymph 
node territories  [32–34] . This also explains the occurrence 
of iterative involvement of the pancreas and metastasis to 
the contralateral kidney and adrenal glands which are not 
uncommon features of RCCs  [13] .
 Conclusion 
 Pancreatic metastases of RCCs can be treated by radi-
cal resection with low morbidity and mortality. Patients 
with small and singular lesions benefit most from the re-
section as they display good long-term survival. There-
fore, as metastases can occur several years after resection 
of the primary tumor, long-term cancer surveillance 
should be performed to ensure early diagnosis and treat-
ment.
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